Paper 1: Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension

• RAAS-targeting agents: ACE inhibitors (e.g., lisinopril, ramipril), angiotensin receptor blockers (ARBs, e.g., valsartan, candesartan), and direct renin inhibitors (aliskiren - the only approved drug in this class, shown to reduce BP in a dose-dependent manner but not recommended as first-line)
• Calcium channel blockers (CCBs): Dihydropyridines (amlodipine, nifedipine) and non-dihydropyridines (verapamil, diltiazem). ALLHAT data showed amlodipine lowered SBP 1.2 mmHg more than lisinopril. CCBs preferred over ACEi in Afro-Caribbean patients.
• Beta-blockers, diuretics, vasodilators: Reviewed with standard mechanistic and clinical data.

• Non-steroidal mineralocorticoid receptor antagonists: Esaxerenone (approved in Japan for essential hypertension) - longer half-life (18.6 h vs 5 h for eplerenone), causing more stable 24-hour BP reductions; less hyperkalemia than eplerenone.
• Aminopeptidase A inhibitors (Firabestat/BR150): Inhibit brain conversion of angiotensin II to angiotensin III, decreasing vasopressin release and increasing diuresis. Phase III trials showed 18% greater SBP decrease vs placebo; potentially useful in Black populations.
• SGLT-2 inhibitors (Bexagliflozin/EGT0001442): Phase III trial in 1,700 T2DM patients across 10 countries; modest SBP reduction of 9.8 mmHg vs 6.9 mmHg in placebo arm.
• Nesiritide (recombinant B-type natriuretic peptide): Phase I/II trial; leads to vasodilation, natriuresis, diuresis.

Paper 2: Pharmacotherapy for Essential Hypertension - A Brief Review

• ACC/AHA 2017: Hypertension = BP ≥ 130/80 mmHg; pharmacotherapy for Stage 1 (130-139/80-89) only if ASCVD or 10-year risk ≥10%; pharmacotherapy for all Stage 2 (≥140/90).
• ISH 2020: Treat grade 1 (140-159/90-99) immediately if ASCVD or high risk; all grade 2 (≥160/100) regardless of risk.
• ESC/ESH 2018: Treat grade 1 with renal disease, high ASCVD risk, or organ damage; all grade 2 and 3 regardless.

• Three first-line classes: thiazide diuretics, ACEi/ARBs, and CCBs - all have similar efficacy in preventing CV complications with minimal differences between classes.
• A meta-analysis of 123 studies (613,815 patients) showed 10 mmHg SBP reduction significantly reduces major CV events and mortality. Beta-blockers were inferior to other classes for this endpoint; CCBs were superior for stroke prevention but inferior for heart failure prevention; diuretics were superior for heart failure prevention.
• Cochrane review confirmed thiazides, ACEi, and CCBs are equivalent first-line options; beta-blockers or high-dose thiazides may be less effective.

• Generic vs. brand-name medications: generic equivalents are equally effective and far more affordable.
• Combination therapy: early single-pill combinations improve adherence and BP control vs. sequential monotherapy titration.
• Special populations: diabetes (ACEi/ARBs preferred), CKD (ACEi/ARBs reduce proteinuria), heart failure (ACEi/ARBs + beta-blockers), resistant hypertension (add MRA as 4th agent).

Paper 3: Initial Treatment of Hypertension (Clinical Practice)

• Hypertension is universal and increases with age. The 2017 ACC/AHA guideline lowered the threshold to ≥130/80 mmHg, raising prevalence from 31.9% to 45.6% in US adults. BP control at <130/80 drops from 61% (using old ≥140/90 definition) to only 46.6%.
• Hypertension leads to stroke, coronary disease, heart failure, CKD, and death. Global deaths from SBP ≥140 mmHg rose from 97.9 to 106.3 per 100,000 between 1990-2015.

• Emphasizes the importance of accurate measurement: automated cuff devices reduce "white coat" effect; ambulatory BP monitoring distinguishes masked hypertension (normal office, high at home) from white coat hypertension.
• Evaluation includes history of secondary causes (NSAIDs - directly relevant to vignette patient - stimulants, renal/renovascular/endocrine causes), physical exam for target-organ damage (cardiac, vascular, renal, retinal, neurological), and baseline labs.

• Potassium intake ≥3,500-5,000 mg/day: average SBP reduction 4.3 mmHg.
• DASH diet: maximizes BP lowering; contains ~2,300 mg sodium/day.
• Physical activity (≥150 min/week aerobic): reduces SBP by ~4.88 mmHg vs control.
• Whole dietary patterns, vegetarian diets: SBP reduction ~5.5/3.0 mmHg vs non-vegetarian.

• First-line: thiazide/thiazide-like diuretics, ACEi/ARBs, CCBs (per ACC/AHA 2017 and JNC-8).
• Longer-acting thiazide-like agents (chlorthalidone, indapamide) more effective than hydrochlorothiazide.
• Special considerations for CKD, diabetes, heart failure all reviewed with specific drug recommendations.
• The clinical vignette patient should: stop naproxen (NSAID raises BP), lose weight, moderate alcohol, and initiate pharmacotherapy.

Paper 4: Hypertension Pharmacological Treatment in Adults - A WHO Guideline Executive Summary

1. When to initiate pharmacotherapy:
   • Initiate for all adults with confirmed BP ≥140/90 mmHg (regardless of CV risk).
   • For adults with SBP 130-139/DBP 80-89 mmHg, initiate pharmacotherapy only if established CVD or high CVD risk is present.
2. BP treatment targets:
   • Primary target: SBP <130 mmHg (if tolerated).
   • Secondary target: DBP <80 mmHg.
3. Drug choice:
   • Three recommended first-line classes: thiazide/thiazide-like diuretics, ACEi/ARBs, and long-acting dihydropyridine CCBs.
   • ACEi and ARBs should not be combined (increases adverse effects without additional benefit).
   • Single-pill combination (SPC) therapy is recommended over free-combination therapy to improve adherence.
4. Initial therapy - mono vs. dual:
   • For most adults with BP ≥140/90 mmHg: start with dual combination therapy (preferably SPC).
   • For adults with BP ≥160/100 mmHg: start with two drugs as standard practice.
   • Monotherapy is acceptable for older, frail patients or those with BP only just above threshold.
5. Follow-up intervals:
   • Monthly until target is reached, then every 3-6 months once stable.
6. Task-sharing:
   • Non-physician health care workers (nurses, pharmacists, community health workers) can play a meaningful role in hypertension management, particularly in LMICs.

Paper 5: Treatment of Hypertension - A Review

• Weight loss, sodium reduction, potassium supplementation, DASH diet, physical activity, alcohol moderation.
• Individual effects are partially additive and enhance drug efficacy.

• Based on BP level AND atherosclerotic CVD risk.
• First-line drugs: thiazide or thiazide-like diuretics (hydrochlorothiazide or chlorthalidone), ACEi or ARB (e.g., enalapril or candesartan), CCB (e.g., amlodipine).
• Chlorthalidone and indapamide (longer-acting) are more effective than hydrochlorothiazide for BP lowering and CVD protection.

• Most adults <65 years: SBP/DBP <130/80 mmHg.
• Adults ≥65 years: SBP <130 mmHg.
• A 10 mmHg SBP reduction decreases CVD event risk by approximately 20-30%.

• Potassium-sparing diuretics (amiloride, triamterene): minimally effective for BP; used to counteract hypokalemia.
• Loop diuretics (furosemide, torsemide): preferred when GFR <30 or in symptomatic heart failure.
• Alpha-1 antagonists (doxazosin): SBP reduction 10.6 mmHg; useful when increased SNS activity suspected.
• Central alpha-2 agonists (clonidine): last-line due to CNS effects and risk of hypertensive crisis on withdrawal.
• Direct vasodilators (hydralazine, minoxidil): reserved for resistant cases; must be used with diuretic and beta-blocker.

• Home BP monitoring with upper-arm automated cuffs is preferred; direct electronic transmission of readings facilitates prompt medication titration.
• Reassess at 1 month after initiation, then monthly until target is reached, then every 3 months.

Quick Comparison at a Glance

Amlodipine Across All 5 Papers

Mechanism of Action

Dosing

• Dose range: 2.5-10 mg once daily (Taler, NEJM 2018; Carey et al., JAMA 2022)
• Once-daily dosing is possible due to its long half-life

Guideline Status - First-Line Drug

• Carey et al. (JAMA 2022): "First-line drug therapy consists of a thiazide or thiazide-like diuretic... an ACEi or ARB... and a calcium channel blocker such as amlodipine"
• Taler (NEJM 2018): Listed as first-line CCB or add-on as second/third agent
• WHO Guideline (Al-Makki 2022): Long-acting dihydropyridine CCBs (amlodipine is the prototype) are one of three recommended first-line classes
• Carey (JAMA): "Amlodipine preferred CCB if tolerated"

Clinical Trial Evidence

BP Reduction Magnitude

• SBP reduction vs. placebo: 15.9 mmHg (95% CI: 22.2 to 9.5) - the highest of any first-line drug class in Carey et al.'s drug table (JAMA 2022)
• A 10 mmHg SBP reduction with any antihypertensive reduces CVD event risk by ~20-30%

Adverse Effects

• Dose-dependent peripheral edema (most common - "edema of the legs and feet") (Taler; Carey)
• Flushing, tachycardia, dizziness (Ojha)
• Gingival hyperplasia (Carey)
• May worsen proteinuria (Taler)
• May worsen left ventricular outflow tract obstruction (Taler)

Special Populations & Contraindications

• Preferred over ACEi in Afro-Caribbean/Black patients - ALLHAT showed higher rates of stroke, peripheral artery disease, and angina hospitalization in the ACEi (lisinopril) group vs. the amlodipine group (Ojha)
• Avoid in HFrEF (heart failure with reduced ejection fraction) - dihydropyridine CCBs are not used here (Carey)
• Non-dihydropyridines (verapamil, diltiazem) - not amlodipine - cause cardiac depression/AV block; verapamil causes constipation

Combination Therapy

• Amlodipine + perindopril (ASCOT-BPLA): superior CV outcomes vs. atenolol-based regimen
• Valsartan/amlodipine fixed combination (chronotherapy study): improved BP control when dosed at bedtime (cited in Heidari)
• The WHO guideline and Carey et al. both support single-pill combinations including a CCB like amlodipine for improved adherence